PDT Partners LLC Has $942,000 Stock Holdings in ICU Medical, Inc. $ICUI

Key Points

• PDT Partners LLC reduced its stake in ICU Medical, Inc. by 29.4% during Q1, selling 2,821 shares to hold 6,781 shares valued at $942,000.
• ICU Medical reported earnings of $2.10 per share, beating estimates by $0.66, despite an 8.0% decline in revenue compared to the previous year.
• Recent analyst ratings for ICU Medical reflect a consensus of "Buy," with Piper Sandler issuing an "overweight" rating and a target price of $145.00.

PDT Partners LLC decreased its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 29.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,781 shares of the medical instruments supplier's stock after selling 2,821 shares during the quarter. PDT Partners LLC's holdings in ICU Medical were worth $942,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. GAMMA Investing LLC lifted its stake in ICU Medical by 27.2% in the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after acquiring an additional 153 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of ICU Medical in the 1st quarter valued at approximately $859,000. Vontobel Holding Ltd. bought a new position in shares of ICU Medical in the 1st quarter valued at approximately $235,000. Envestnet Asset Management Inc. increased its position in ICU Medical by 8.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 20,269 shares of the medical instruments supplier's stock worth $2,815,000 after buying an additional 1,534 shares during the period. Finally, Xponance Inc. increased its position in ICU Medical by 5.3% in the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier's stock worth $238,000 after buying an additional 86 shares during the period. Institutional investors and hedge funds own 96.10% of the company's stock.

Insider Transactions at ICU Medical

In other ICU Medical news, Director David C. Greenberg purchased 1,200 shares of the stock in a transaction on Wednesday, August 27th. The stock was bought at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the acquisition, the director directly owned 7,960 shares of the company's stock, valued at $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vivek Jain acquired 21,929 shares of ICU Medical stock in a transaction dated Thursday, August 14th. The shares were purchased at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the transaction, the chief executive officer directly owned 130,149 shares of the company's stock, valued at $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.50% of the company's stock.

ICU Medical Price Performance

ICU Medical stock traded down $0.93 on Tuesday, reaching $129.65. The company's stock had a trading volume of 32,228 shares, compared to its average volume of 266,444. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. The company has a market cap of $3.20 billion, a price-to-earnings ratio of -85.17 and a beta of 0.86. The business's fifty day moving average price is $126.48 and its 200 day moving average price is $134.22. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, topping analysts' consensus estimates of $1.44 by $0.66. The company had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The firm's quarterly revenue was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ICUI has been the topic of a number of research reports. Raymond James Financial lowered their price objective on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research report on Friday, August 8th. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Piper Sandler began coverage on ICU Medical in a research note on Friday, August 15th. They issued an "overweight" rating and a $145.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $179.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.